Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B

  • Technology appraisal guidance
  • TA96
  • Published: 
Download guidance (PDF)

1 Guidance

This guidance was partially updated by NICE clinical guideline 165 in June 2013. See About this guidance for more information.

This guidance does not apply to people with chronic hepatitis B known to be co-infected with hepatitis C, hepatitis D or HIV.

1.1 Peginterferon alfa-2a is recommended as an option for the initial treatment of adults with chronic hepatitis B (HBeAg-positive or HBeAg-negative), within its licensed indications.

1.2 This recommendation has been replaced by recommendation 1.5.13 in NICE clinical guideline 165.

1.3 This recommendation has been replaced by recommendation 1.5.14 in NICE clinical guideline 165.

1.4 This recommendation has been replaced by recommendation 1.5.15 in NICE clinical guideline 165.